On September 11, 2026, Park Ha Biological Technology Co., Ltd. closed a private investment in public equity (PIPE) transaction with non-U.S. investors. The company issued and sold 1,845,452 Class A ordinary shares at $2.75 per share, generating aggregate gross proceeds of approximately US$2,970,000 before offering expenses. Concurrently, the purchasers received warrants to buy an additional 1,845,452 Class A ordinary shares, exercisable immediately at $1.10 per share with a five-year term and a conversion ratio of two-and-a-half shares per warrant. The net proceeds are intended for general working capital and corporate purposes. Park Ha Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on biological technology development.

On August 3, 2026, Park Ha Biological Technology Co., Ltd. completed a private placement transaction with non-U.S. investors, issuing 10,000,000 Class A ordinary shares and warrants to purchase up to 2,000,000 additional shares. The securities were sold at $0.18 per share and accompanying warrant, generating approximately $1,800,000 in aggregate gross proceeds before offering expenses. The warrants are immediately exercisable for five years at an exercise price of $0.18 per share. The company intends to use the net proceeds for general working capital and corporate purposes. Park Ha Biological Technology Co., Ltd. operates in the biological technology industry.

Park Ha Biological Technology Co., Ltd. announced the successful passage of all resolutions at its Extraordinary General Meeting and Class A Meeting held on July 13, 2026. Shareholders approved increasing the company's authorized share capital from US$3,000,000 to US$300,000,000 by creating 297,000,000,000 additional ordinary shares. The Board was authorized to execute share consolidations (2-for-1 to 5,000-for-1) and subdivisions (2-for-1 to 100-for-1) over the next three years. Additionally, a special resolution was passed to increase the voting rights of Class B Ordinary Shares from 20 votes to 100 votes per share. The company operates in the biotechnology industry.

Park Ha Biological Technology Co., Ltd. filed a membership application with the Personal Care Products Council on July 1, 2026, to establish a compliance framework for the North American market and facilitate its entry into Amazon's North America marketplace. The application is currently under review. The company operates in the personal care and biological technology industry, providing products for the cosmetics and skincare industry.

Park Ha Biological Technology Co., Ltd. announced on June 29, 2026, that it is initiating cooperation with Amazon and preparing for entry into the North American personal care market. The company is currently advancing four workstreams: store qualification registration, Amazon brand registration, compliance framework establishment, and localized product operation strategies. Park Ha Biological Technology Co., Ltd. operates in the personal care and skincare products industry and develops scientifically formulated skincare products.